Naramig (Naratriptan)

Naratriptan works by selectively stimulating serotonin 5‑HT1B and 5‑HT1D receptors in the brain. This action causes constriction of dilated cranial blood vessels and blocks the release of inflammatory neuropeptides from trigeminal nerves, interrupting the migraine cascade and reducing pain.

The appropriate dose of Naramig is determined by the prescribing healthcare professional based on the patient’s clinical condition, age, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

The safety of naratriptan in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Naramig, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Naratriptan belongs to the triptan class, which is generally more specific for migraine than non‑specific analgesics. Compared with other triptans, naratriptan has a longer half‑life, allowing a single dose to cover prolonged attacks, but individual response and tolerability may vary.

Naramig tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Naramig is taken orally with a glass of water. It is usually administered at the first sign of a migraine attack. Patients should swallow the tablet whole and avoid crushing or chewing it unless otherwise directed by a healthcare professional.

Serious risks include cardiovascular events such as myocardial ischemia or stroke, especially in patients with underlying vascular disease, and serotonin syndrome when combined with other serotonergic drugs. Any signs of chest pain, severe headache, or serotonin toxicity require immediate medical attention.

Naramig should not be used by individuals with uncontrolled hypertension, a history of coronary artery disease, prior stroke or transient ischemic attack, or those taking ergot alkaloids, MAO inhibitors, or other triptans. Contraindications must be confirmed by a qualified prescriber.